Skip to main content

Table 4 The predicted mean CD4+ change of patients treated with AZT and TDF based regimens at JUSH, September 2012 to July 2014

From: Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study

Status Status Delta-method t [95% CI] P value
Margins Standard error
Unexposed AZT3TC/NVP 319.11 19.34 16.50 281.02,357.20 P < 0.001
AZT/3TC/EFV 281.54 18.39 15.31 245.31,317.77 P < 0.001
Exposed TDF/3TC/NVP 295.73 18.39 16.08 259.50,331.96 P < 0.001
TDF/3TC/EFV 347.65 18.39 18.90 311.42,383.89 P < 0.001